Filing Details

Accession Number:
0000873303-10-000025
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-06-10 13:00:00
Reporting Period:
2010-06-09
Filing Date:
2010-06-10
Accepted Time:
2010-06-10 13:29:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
873303 Avi Biopharma Inc AVII Pharmaceutical Preparations (2834) 930797222
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1223756 R Anthony Chase 3450 Monte Villa Parkway, Suite 101
Bothell WA 98021
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-06-09 1,000 $1.40 345,967 No 4 P Direct
Common Stock Acquisiton 2010-06-09 5,600 $1.40 351,567 No 4 P Direct
Common Stock Acquisiton 2010-06-09 100 $1.42 351,667 No 4 P Direct
Common Stock Acquisiton 2010-06-09 6,900 $1.42 358,567 No 4 P Direct
Common Stock Acquisiton 2010-06-09 700 $1.42 359,267 No 4 P Direct
Common Stock Acquisiton 2010-06-09 100 $1.42 359,367 No 4 P Direct
Common Stock Acquisiton 2010-06-09 300 $1.42 359,667 No 4 P Direct
Common Stock Acquisiton 2010-06-09 31,800 $1.42 391,467 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Common Stock Purchase Warrants $1.78 2010-02-25 2014-08-25 140,000 350,000 Direct
Common Stock Non-Qualified Stock Option (right to buy) $1.24 2011-04-20 2020-04-20 60,000 60,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2014-08-25 140,000 350,000 Direct
2020-04-20 60,000 60,000 Direct
Footnotes
  1. Mr. Chase holds 350,000 warrants to purchase common stock. Each warrant can be exercised to purchase 4/10 (or 0.4) of a share of common stock. Thus, Mr. Chase's 350,000 warrants are exercisable to purchase 140,000 shares of common stock at $1.78 per share.
  2. Such options shall have a four-year vesting period commencing on the Grant Date, 1/4th of the shares vest and become exercisable on the earlier of one year after the Grant Date or the commencement of the next succeeding annual meeting of shareholders; 1/4th of the shares vest and become exercisable on the earlier of two years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders, 1/4th of the shares vest and become exercisable on the earlier of three years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders and 1/4th of the shares vest and become exercisable on the earlier of four years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders.